. 2020 Apr 21;11:673. doi: 10.3389/fimmu.2020.00673

TABLE 1.

Plasma and cellular biomarkers for post-HCT outcomes.

Protein	Study	No. of patients in the study	Association direction	Diagnosis timepoint (median day post-HCT)	Prognostic timepoint (median day post-HCT)	References
Plasma aGVHD
4 biomarker panel: IL-2-receptor-α, hepatocyte growth factor (HGF), IL-8 tumor necrosis factor receptor-1	Paczesny 2009	42+282^†+142^†	Increased	28	ND	52
Interleukin-6 (IL-6)	McDonald 2015	74^†+76 ^†	Increased	28	Not significant	53
	Kennedy 2014	53	Increased (3–14), then decreased	30	7–14	54
Stimulation 2 (ST2)	Vander Lugt 2013	20+381^†+673+75	Increased	28	14	55
	Levine 2015	328+164^†+300^†	Increased	28	ND	56
	Abu Zaid 2017	211 patients (independent cohort post-validation)	Increased	28	ND	58
	McDonald 2015	74^†+76^†	Increased	28	Not significant	53
	Hartwell 2017	620+309^†+358^†	Increased	ND	7	59
	Major-Monfried 2018	236+142^†129^†	Increased	ND	7	64
	McDonald 2017	165	Increased	ND	14	65
T cell immunoglobulin domain and mucin domain (TIM3)	McDonald 2015	74^†+76^†+167*	Increased	28	14	53
	Abu Zaid 2017	211 patients (independent cohort post-validation)	Increased	28	ND	58
AREG/EGF ratio	Holtan 2016	105+50^†	Increased	160	ND	66
Skin specific
Elafin	Paczesny 2010	522+492^†	Increased	28	ND	67
	Bruggen 2015	59	Increased	28	ND	68
Liver specific
REG3 α, HGF, and Keratin 18 (KRT18)	Harris 2012	954, 3 centers	Increased	14	28	69
GI specific
Regenerating islet-derived 3-α (REG3 α)	Ferrara 2011	20+871^†143^†	Increased	28	ND	71
T cell immunoglobulin domain and mucin domain (TIM3)	Hansen 2013	20+127^†+22^†	Increased	28	ND	73
Cellular aGVHD
Regulatory T cells	Magenau 2010	215	Decreased	3–14	28	19
CD146+ T cells	Li 2016	20+214^†	Increased	ND	14	28
CD30	Chen 2012	53	Increased	ND	ND	80
	Chen 2017	34	Increased	ND	NA	81
Invariant natural killer T cells (iNKT)	Chaidos 2012	57	Increased	ND	NA	82
Plasma chronic GVHD
sBAFF	Sarantopoulos 2007	104	Increased	480	NA	93
	Fujii 2008	80	Increased	171 (early^&), 429 (late^&)	NA	94
	Kitko 2014	35+109^†+211^†	Increased, and not validated in independent cohort	154⁺, 256 (early^&), 619 (late^&)	NA	95
	Kariminia 2016	23+198^†+83^†	Increased	203,174	NA	96
	Saliba 2017	341	Increased/decreased #	189	NA	98
CXCL9	Kitko 2014	35+109^†+211^†	Increased	154⁺, 256 (early^&), 619 (late^&)	NA	95
	Yu 2016	53+211^†+180^†	Increased	210⁺,203^&	100	99
	Kariminia 2016	23+198^†+83^†	Increased, and not validated in independent cohort	203⁺,174^&	NA	96
	Hakim 2016	26+83^†	Increased	132	NA	42
	Abu 2017	211	Increased	NA	100, 180, 365 (time dependent analysis)	58
CXCL10	Kariminia 2016	23+198^†+83^†	Increased	203⁺,174^&	NA	96
	Hakim 2016	26+83^†	Increased	132	NA	42
	Ahmed 2016	78+37	Increased	132	NA	97
Four protein panel (CXCL9, ST2, OPN, MMP3)	Yu 2016	53+211^†+180^†	Increased	210,203	100	99
MMP3	Liu 2016	76 (BOS)	Increased	531	NA	100
CCL15	Du 2018	211^†+792^†	Increased at onset, but not prognostic	203	100	101
Cellular chronic GVHD
CD163	Inamoto 2017	40+127^†	Increased	NA	80	102
B cells
TLR9⁺	She 2007	54	Increased	171 (early), 429 (late)	NA	103
CD21^low	Greinix 2008	70	Increased	1428	NA	104
	Kuzmina 2013	136	Increased	143	NA	105
BAFF/B cell ratio	Sarantopoulos 2009	57	Increased	180	NA	23
Tregs	Zorn 2005	57	Decreased	720	NA	20
CD4⁺CD146⁺CCR5⁺	Forcade 2017	40	Increased	942	NA	29
TFH	Forcade 2016	66	Decreased	867	NA	25

ND, not done; NA, not applicable; ^†Patient number in validation cohort 1 and cohort 2; ⁺cohort 1 and ^&cohort 2.